<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="201225">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00470366</url>
  </required_header>
  <id_info>
    <org_study_id>07-044</org_study_id>
    <secondary_id>MSKCC-07044</secondary_id>
    <nct_id>NCT00470366</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy and Pegfilgrastim in Treating Patients With Previously Untreated Germ Cell Tumors</brief_title>
  <official_title>Phase II Trial of Paclitaxel, Ifosfamide, and Cisplatin in Previously Untreated Intermediate and Poor Risk Germ Cell Tumor Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as cisplatin, ifosfamide, and paclitaxel, work
      in different ways to stop the growth of tumor cells, either by killing the cells or by
      stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill
      more tumor cells. Colony-stimulating factors, such as pegfilgrastim, may increase the number
      of immune cells found in bone marrow or peripheral blood and may help the immune system
      recover from the side effects of chemotherapy.

      PURPOSE: This phase II trial is studying the side effects and how well giving combination
      chemotherapy together with pegfilgrastim works in treating patients with previously
      untreated germ cell tumors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Determine the efficacy of chemotherapy comprising paclitaxel, ifosfamide, and cisplatin
           in combination with pegfilgrastim in patients with previously untreated intermediate-
           or poor-risk germ cell tumors.

        -  Determine the safety of this regimen in these patients.

        -  Determine the toxicity of this regimen in these patients.

      OUTLINE: Patients receive paclitaxel IV over 120-180 minutes on days 1 and 2, cisplatin IV
      over 30 minutes and ifosfamide IV over 120 minutes on days 1-5, and pegfilgrastim
      subcutaneously on day 6. Treatment repeats every 21 days for up to 4 courses in the absence
      of disease progression or unacceptable toxicity.

      Some patients may required surgery after chemotherapy and, if viable non-teratomatous germ
      cell tumor is found in the surgical specimen and there is no interval disease progression,
      these patients may receive 1-2 more courses of chemotherapy after surgery.

      After completion of study treatment, patients are followed up at 28 days and then every 2
      months for up to 1 year.

      PROJECTED ACCRUAL: A total of 55 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of complete response</measure>
    <time_frame>At the completion of therapy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>At the completion of therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of courses required to achieve maximal response</measure>
    <time_frame>At the completion of therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>At the completion of therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>At the completion of therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>At the completion of therapy</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Brain and Central Nervous System Tumors</condition>
  <condition>Extragonadal Germ Cell Tumor</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Teratoma</condition>
  <condition>Testicular Germ Cell Tumor</condition>
  <arm_group>
    <arm_group_label>Paclitaxel, Ifosfamide, and Cisplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>-Paclitaxel is administered first, 120 mg/m2 on days 1 and 2 every three weeks for four cycles. Cisplatin is administered at 20 mg/m2 over approximately 30 minutes daily for five days every three weeks for four courses. -The ifosfamide is given last with 1200 mg/m2 daily for five days every three weeks for four cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>pegfilgrastim</intervention_name>
    <arm_group_label>Paclitaxel, Ifosfamide, and Cisplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <arm_group_label>Paclitaxel, Ifosfamide, and Cisplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ifosfamide</intervention_name>
    <arm_group_label>Paclitaxel, Ifosfamide, and Cisplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
    <arm_group_label>Paclitaxel, Ifosfamide, and Cisplatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed germ cell tumor meeting 1 of the following criteria:

               -  Poor risk, defined by any of the following:

                    -  Testis or retroperitoneal primary site nonseminoma histology without
                       visceral metastases but with &quot;poor-risk&quot; markers, defined by any of the
                       following:

                         -  Pretreatment serum lactate dehydrogenase (LDH) &gt; 10 times upper limit
                            of normal (ULN)

                         -  Pretreatment serum human chorionic gonadotropin (HCG) &gt; 50,000 IU/L

                         -  Pretreatment serum alpha fetoprotein (AFP) &gt; 10,000 ng/mL

                    -  Testis or retroperitoneal primary site nonseminoma histology with one or
                       more nonpulmonary visceral metastases, including any of the following
                       (regardless of serum tumor marker values):

                         -  Bone metastases

                         -  Brain metastases

                         -  Hepatic metastases

                         -  Any nonpulmonary metastases (i.e., skin, spleen)

                    -  Mediastinal primary site nonseminoma histology regardless of serum tumor
                       marker levels or presence/absence of visceral metastases

               -  Modified intermediate risk, defined by any of the following:

                    -  Testis or retroperitoneal primary site nonseminoma histology with no
                       nonpulmonary visceral metastases, and with any of the following serum
                       marker values:

                         -  Pretreatment serum LDH 3.0-10 times ULN

                         -  Pretreatment serum HCG 5,000-50,000 IU/L

                         -  Pretreatment serum AFP 1,000-10,000 ng/mL

                    -  Seminoma histology with one or more nonpulmonary visceral metastases,
                       including any of the following (regardless of serum tumor marker values or
                       primary site):

                         -  Bone metastases

                         -  Brain metastases

                         -  Hepatic metastases

                         -  Any nonpulmonary visceral metastases (i.e., skin, spleen)

          -  Previously untreated disease

          -  Measurable or evaluable disease

        PATIENT CHARACTERISTICS:

          -  WBC ≥ 3,000/mm^3

          -  Platelet count ≥ 100,000/mm^3

          -  Creatinine normal or creatinine clearance &gt; 50 mL/min (unless renal dysfunction is
             due to tumor obstructing the ureters)

          -  AST and ALT ≤ 3 times ULN

          -  Bilirubin ≤ 2.0 times ULN

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  No concurrent malignancy except for nonmelanoma skin cancer

          -  No known HIV positivity

          -  No active infections

        PRIOR CONCURRENT THERAPY:

          -  Recovered from prior surgery

          -  More than 30 days since prior radiotherapy and recovered (unless evidence of
             progressive disease has been documented)

          -  No prior chemotherapy

          -  No other concurrent cytotoxic therapy

          -  Concurrent radiotherapy and surgery allowed for treatment of brain metastases
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Darren Feldman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert J. Motzer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>USC/Norris Comprehensive Cancer Center and Hospital</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90089-9181</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <lastchanged_date>June 16, 2016</lastchanged_date>
  <firstreceived_date>May 3, 2007</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage II malignant testicular germ cell tumor</keyword>
  <keyword>stage III malignant testicular germ cell tumor</keyword>
  <keyword>testicular choriocarcinoma and embryonal carcinoma</keyword>
  <keyword>testicular choriocarcinoma and seminoma</keyword>
  <keyword>testicular choriocarcinoma and teratoma</keyword>
  <keyword>testicular choriocarcinoma and yolk sac tumor</keyword>
  <keyword>testicular choriocarcinoma</keyword>
  <keyword>testicular embryonal carcinoma and seminoma</keyword>
  <keyword>testicular embryonal carcinoma and teratoma with seminoma</keyword>
  <keyword>testicular embryonal carcinoma and teratoma</keyword>
  <keyword>testicular embryonal carcinoma and yolk sac tumor with seminoma</keyword>
  <keyword>testicular embryonal carcinoma and yolk sac tumor</keyword>
  <keyword>testicular embryonal carcinoma</keyword>
  <keyword>testicular seminoma</keyword>
  <keyword>testicular yolk sac tumor and teratoma with seminoma</keyword>
  <keyword>testicular yolk sac tumor and teratoma</keyword>
  <keyword>testicular yolk sac tumor</keyword>
  <keyword>stage I malignant testicular germ cell tumor</keyword>
  <keyword>adult central nervous system germ cell tumor</keyword>
  <keyword>ovarian choriocarcinoma</keyword>
  <keyword>ovarian dysgerminoma</keyword>
  <keyword>ovarian embryonal carcinoma</keyword>
  <keyword>ovarian yolk sac tumor</keyword>
  <keyword>ovarian immature teratoma</keyword>
  <keyword>ovarian mature teratoma</keyword>
  <keyword>ovarian monodermal and highly specialized teratoma</keyword>
  <keyword>ovarian polyembryoma</keyword>
  <keyword>ovarian mixed germ cell tumor</keyword>
  <keyword>stage IV ovarian germ cell tumor</keyword>
  <keyword>stage IV extragonadal seminoma</keyword>
  <keyword>stage I extragonadal non-seminomatous germ cell tumor</keyword>
  <keyword>stage II extragonadal non-seminomatous germ cell tumor</keyword>
  <keyword>stage III extragonadal non-seminomatous germ cell tumor</keyword>
  <keyword>stage IV extragonadal non-seminomatous germ cell tumor</keyword>
  <keyword>adult teratoma</keyword>
  <keyword>testicular immature teratoma</keyword>
  <keyword>testicular mature teratoma</keyword>
  <keyword>stage IA ovarian germ cell tumor</keyword>
  <keyword>stage IB ovarian germ cell tumor</keyword>
  <keyword>stage IC ovarian germ cell tumor</keyword>
  <keyword>stage IIA ovarian germ cell tumor</keyword>
  <keyword>stage IIB ovarian germ cell tumor</keyword>
  <keyword>stage IIC ovarian germ cell tumor</keyword>
  <keyword>stage IIIA ovarian germ cell tumor</keyword>
  <keyword>stage IIIB ovarian germ cell tumor</keyword>
  <keyword>stage IIIC ovarian germ cell tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Neoplasms, Germ Cell and Embryonal</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
    <mesh_term>Teratoma</mesh_term>
    <mesh_term>Testicular Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Isophosphamide mustard</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Ifosfamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
